Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Astellas Bids For CV Therapeutics

by Lisa M. Jarvis
February 2, 2009 | A version of this story appeared in Volume 87, Issue 5

Astellas Pharma has made a hostile bid for CV Therapeutics, a Palo Alto, Calif.-based biotech that develops small-molecule drugs to treat cardiovascular diseases. The Japanese company says CV Therapeutics' board of directors rejected an all-cash offer made last November of $16.00 per share, valuing the company at $1 billion, and has since refused to engage in talks.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.